Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17β-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: Results from a double-blind, controlled study

John C. Stevenson, Gemma Durand, Elke Kahler, Tomasz Pertyński

Maturitas · 2010 · 55 citations · 19 references

Concepts

References

19